• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Time to shut down NIBR

Quote
"The wave of new drug approvals that had been building at the FDA has broken. According to the official tally of new drug and biologics approvals at the agency, the biopharma industry registered only 27 OKs for new entities in 2013--a sharp plunge from 2012's high of 39 that once again raises big questions about the productivity and sustainability of the world's multibillion-dollar R&D business."

Read more: An ominous trend resurfaces as new drug approvals plunge in 2013 - FierceBiotech http://www.fiercebiotech.com/specia...-new-drug-approvals-plunge-2013#ixzz2rehgSTyl
Subscribe at FierceBiotech
 




Anonymous said:
"The wave of new drug approvals that had been building at the FDA has broken. According to the official tally of new drug and biologics approvals at the agency, the biopharma industry registered only 27 OKs for new entities in 2013--a sharp plunge from 2012's high of 39 that once again raises big questions about the productivity and sustainability of the world's multibillion-dollar R&D business."

Read more: An ominous trend resurfaces as new drug approvals plunge in 2013 - FierceBiotech http://www.fiercebiotech.com/specia...-new-drug-approvals-plunge-2013#ixzz2rehgSTyl
Subscribe at FierceBiotech
Click to expand...

"Although Novartis is known for its strong drug pipeline, the CBCD believes that these possible layoffs may be a direct result of the productivity crisis in pharmaceutical R&D, which may finally have hit the pharmaceutical company. As an article published on November 5, 2013 in the industrial daily, FierceBiotech.com reported “The pharma giant hammered the British community two years ago when it eliminated a major manufacturing operation in Horsham. But the Novartis Institutes for BioMedical Research had committed to keeping its research work going and last fall discussed a major upgrade for the site. Today, though, it confirmed that it will shutter the complex, where investigators concentrated on respiratory programs (2).”
Further evidence is the fact that the company is considering a global restructuring of its entire R&D program. “The move signals a wider "realignment" of (Novartis’) R&D worldwide (2).”
The FiercePharma article continued saying, “There's no immediate word from Novartis on what it intends to do with its huge global R&D effort, which consumes more than $9 billion a year. Novartis has long held the title for the largest R&D budget in the industry…most of the Big Pharmas have triggered some sort of R&D reorganization over the past few years, though Novartis was always one of the few exceptions to the rule (2).”
The CBCD believes that the proposed layoffs and restructuring of Novartis’ global R&D efforts are a direct result of the challenges they face in R&D, and would like to offer to Novartis and other pharmaceutical companies, a new technology to overcome R&D challenges."

http://www.prweb.com/releases/2013/11/prweb11311943.htm
 




The previous posts about R&D spend vs return are true but not the whole story. Primary care development has been relegated offshore so it can be done as "cheaply" as possible. The US price pressure has forced Pharma to be a specialty med focused (onc, trx, orphan) business; developing these compounds are not different than Vegas odds. This mistake is going to take a long time to bite the hand that forced it. By then, we will all have done a stint on LTD or unemployment or will be left withering away in open space.

As required by legal standards, anyone who works in D (of R&D) both global and in the US has more or less been informed that a massive reduction is afoot: there is no safe franchise or function. How NIBR and Basle stay more or less intact in 2014 will be the Wizard's doing.

We aren't in Kansas anymore. Time to make the donuts.
 




Anonymous said:
The previous posts about R&D spend vs return are true but not the whole story. Primary care development has been relegated offshore so it can be done as "cheaply" as possible. The US price pressure has forced Pharma to be a specialty med focused (onc, trx, orphan) business; developing these compounds are not different than Vegas odds. This mistake is going to take a long time to bite the hand that forced it. By then, we will all have done a stint on LTD or unemployment or will be left withering away in open space.

As required by legal standards, anyone who works in D (of R&D) both global and in the US has more or less been informed that a massive reduction is afoot: there is no safe franchise or function. How NIBR and Basle stay more or less intact in 2014 will be the Wizard's doing.

We aren't in Kansas anymore. Time to make the donuts.
Click to expand...

But according to the geniuses here it is all management's fault? I guess that they will have a lot of time to contemplate this while they go back to being post Docs and adjunct professors for the rest of their lives.

What a waste of the pretty new campus in Cambridge!
 




Anonymous said:
But according to the geniuses here it is all management's fault? I guess that they will have a lot of time to contemplate this while they go back to being post Docs and adjunct professors for the rest of their lives.

What a waste of the pretty new campus in Cambridge!
Click to expand...

The entire concept of NIBR - folly, begat from arrogance breast fed on hubris.
 








Re: Time to shut the FUCK UP!

MBA/sales rep = variable costs of business.
Researcher / laboratory = fixed costs ... Business bad, adjust the variable costs- fire dumb shit sales reps ... Increase bottom line.

Na, na NNAA NNAA hey hey hey good-ud bye ... And so long the FN "brilliant marketers"

Dime a dozen and I feel over charged...
nigh-burgh rules, sales reps drool!!!!
 




Re: Time to shut the FUCK UP!

Anonymous said:
MBA/sales rep = variable costs of business.
Researcher / laboratory = fixed costs ... Business bad, adjust the variable costs- fire dumb shit sales reps ... Increase bottom line.

Na, na NNAA NNAA hey hey hey good-ud bye ... And so long the FN "brilliant marketers"

Dime a dozen and I feel over charged...
nigh-burgh rules, sales reps drool!!!!
Click to expand...

Researchers = leaches who mostly produce me-too drugs, if any bit productive. Without NIH and Medicare play money, you are an unproductive nothing.
 




Re: Time to shut the FUCK UP!

Anonymous said:
Researchers = leaches who mostly produce me-too drugs, if any bit productive. Without NIH and Medicare play money, you are an unproductive nothing.
Click to expand...

Empirical proof is the lat 30 years of products that have spilt out of the pharma pipeline in general and the proof ofd that in NIBR's case is the (lack) of products coming from NIBR's. Deservedly, they will get screwed much more than any sales org.
 




rumors circulating in basel now of massive structural changes and huge job losses and even selling or shuttering poor performing franchises in PC such as resp, maybe this time reps are the thin edge of the job loss wedge
 












Anonymous said:
A huge strategic restructuring of NIBR will be announced in the first week of March.
Click to expand...

Please reorganize and dismiss NIBR Basle management – this is a job bank for the friends and Yes men followers of the current head that since years is running everything into the ground and not bringing a single thing to market
 




Anonymous said:
Please reorganize and dismiss NIBR Basle management – this is a job bank for the friends and Yes men followers of the current head that since years is running everything into the ground and not bringing a single thing to market
Click to expand...

The same criteria could be used to fire the sr mgmt at all pharma research facilities. And while we are generalizing this argument it could be used to drastically cut all pharma research.

Wait . . . it is!
 




Anonymous said:
The same criteria could be used to fire the sr mgmt at all pharma research facilities. And while we are generalizing this argument it could be used to drastically cut all pharma research.

Wait . . . it is!
Click to expand...

NIBR Dev is, for all intents and purposes, gone. Like the rest of Novartis, it is a victim of Research that hasn't filled the pipeline. The riddle to success in Research has to be answered so it will be drastically re-orged and paired down.
 




Where to place the blame: management.
Where to hope for triage: NOT NIBR

Management dictates NIBR direction. NIBR cannot deliver based on management direction. Who do you blame? Management, of course.
 












Anonymous said:
Where to place the blame: management.
Where to hope for triage: NOT NIBR

Management dictates NIBR direction. NIBR cannot deliver based on management direction. Who do you blame? Management, of course.
Click to expand...

Hypothesis # 1 -Management dictates direction in all Pharma research orgs. All Pharma research orgs cannot deliver based on management direction. Who do you blame? Management, of course.

Hypothesis # 2 - the basic science that all pharma research is based has reached its peak and the morons who are still employed there make silly claims in its defense because they don't want to go back to a job that pays them what they are worth.

Based on facts we should be able to judge which is more true.
 




Re: Time to kiss my ass and go F-yourself

Just curious how many of those 4,000 jobs cuts are NIBR?
MBAs are the ruination of research and creativity.
So long and thanks for all the stupid repartee...
 




Top Bottom
Back
Quote